ANAHEIM, CA, Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that actor Jeremy Miller appeared on Omaha, Nebraska’s local news channel, KETV NewsWatch ABC 7 Chronicle, on September 9, 2018, supporting the BioCorRx® Recovery Program. This segment also highlighted other individuals that were successfully treated with the BioCorRx® Recovery Program provided by the local I Got Sober treatment center. 

The I Got Sober treatment center, located in Omaha, Nebraska, utilizes the BioCorRx® Recovery Program to assist in treating their patients suffering from substance use disorder. The program is a comprehensive multi-phase outpatient Medication-Assisted-Treatment (MAT) program developed for those suffering with alcohol and/or opioid use disorders. 

“Approximately over 2.5 million Americans are struggling with opioid use disorder and another 15 million Americans suffer from alcohol use disorder. September is National Recovery Month, and we appreciate the support of Jeremy Miller and others shining a light on this national epidemic.  Sadly, 90% of those who try to quit on their own, relapse,” stated Tom Welch, Vice President of Operations at BioCorRx. “The BioCorRx® Recovery Program was designed to help people rebuild their lives by overcoming addiction through the use of our MAT program and the use of the naltrexone implant which is proven to help reduce physical cravings for alcohol and opioids. We are committed to our mission of transforming lives and helping people with substance use disorder live a healthy and rewarding life,” continued Mr. Welch.

The segment can be viewed online at: https://www.ketv.com/article/chronicle-americans-battling-addiction/23050258

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

Released September 12, 2018